In a patient with mild cognitive impairment, Montreal Cognitive Assessment (MoCA) score of 18/30, vitamin B12 deficiency, vitamin D deficiency, normal thyroid‑stimulating hormone (TSH), and elevated plasma phosphorylated tau 217 (p‑tau217), what is the appropriate management?

Management of MCI with Elevated p-Tau217 and Vitamin B12 Deficiency

This patient requires immediate vitamin B12 supplementation (1000 mcg daily, oral or intramuscular) to address the documented deficiency, while the elevated p-tau217 (0.39) indicates underlying Alzheimer's disease pathology that warrants consideration for disease-modifying therapy and close monitoring for progression to dementia.

Interpretation of Laboratory Findings

Vitamin B12 Deficiency (126 pg/mL)

Your patient has clear vitamin B12 deficiency (normal >200-250 pg/mL). While ESPEN guidelines note that only 1.5% of dementia cases are fully reversible from B12 deficiency 1, supplementation can still improve cognitive function in the short term 2. A 2022 study demonstrated significant MMSE improvement (20.5 to 22.9, p<0.001) after B12 supplementation in deficient patients with cognitive impairment 2.

Elevated Plasma p-Tau217

The p-tau217 level of 0.39 is significantly elevated. Recent evidence shows that p-tau217 >0.10 pg/mL has 86.67% sensitivity and 88.89% specificity for detecting Alzheimer's disease pathology 3. Your patient's value of 0.39 strongly indicates underlying AD pathology. The 2022 Alzheimer's Association guidelines confirm that p-tau217 outperforms other plasma biomarkers for distinguishing AD from other dementias and predicting progression from MCI to dementia 4.

MoCA Score of 18/30

This score confirms cognitive impairment beyond "mild" - it suggests moderate impairment. The 2025 ACR guidelines indicate this patient warrants neuroimaging to exclude structural abnormalities and assess for neurodegenerative patterns 5.

Vitamin D (23 ng/mL)

This represents insufficiency (optimal >30 ng/mL). However, 2015 expert recommendations state that vitamin D supplementation should not be used specifically for cognitive decline prevention or correction 6. Correct the deficiency for general health (not cognitive) benefits.

Normal TSH

This appropriately excludes thyroid dysfunction as a reversible cause.

Recommended Management Algorithm

Immediate Actions (Within 1 Week)

1. Start Vitamin B12 Supplementation

   • Dose: 1000 mcg daily (oral or intramuscular)
   • Duration: Minimum 3 months initially
   • Rationale: B12 therapy improves cognition only in deficient patients (<150 pmol/L or ~200 pg/mL) 7
   • Recheck B12 and homocysteine in 2-3 months 2

2. Correct Vitamin D

   • Dose: 1000-2000 IU daily
   • Target: >30 ng/mL for general health
   • Do NOT expect cognitive benefit 6, 1

3. Order Brain MRI Without Contrast

   • Purpose: Exclude structural lesions (mass, subdural hematoma, NPH)
   • Assess hippocampal atrophy and vascular changes
   • The 2025 ACR guidelines recommend MRI as initial imaging for MCI 5

Within 1-3 Months

1. Reassess Cognition After B12 Repletion

   • Repeat MoCA after 2-3 months of B12 therapy
   • If improvement occurs, continue monitoring
   • If no improvement or decline continues, the elevated p-tau217 indicates AD progression

2. Consider Confirmatory Amyloid Testing

   • The elevated p-tau217 (0.39) has high specificity for AD pathology
   • If considering disease-modifying therapy (lecanemab, donanemab), confirm with:
     • Amyloid PET scan, OR
     • CSF biomarkers (Aβ42/Aβ40 ratio, p-tau)
   • The 2024 recommendations support using blood biomarkers for triaging to confirmatory testing 8

Ongoing Management

1. Disease-Modifying Therapy Consideration

   • If amyloid-positive and patient has MCI due to AD (not dementia stage yet)
   • Eligible for anti-amyloid monoclonal antibodies
   • Requires MRI monitoring for ARIA (amyloid-related imaging abnormalities)

2. Monitor for Progression

   • Repeat MoCA every 6 months
   • The combination of elevated p-tau217 and MCI predicts high risk of progression to dementia 4
   • P-tau217 >0.10 pg/mL has been associated with future cognitive decline in MCI patients 9

Critical Pitfalls to Avoid

Do not attribute all cognitive impairment to B12 deficiency alone. The elevated p-tau217 indicates concurrent AD pathology that will not reverse with B12 supplementation 1, 7. Only the component potentially related to B12 deficiency may improve.

Do not delay neuroimaging. A MoCA of 18/30 with elevated p-tau217 requires structural imaging to exclude other treatable causes and establish baseline for monitoring 5.

Do not supplement with multiple vitamins expecting cognitive benefit. ESPEN guidelines strongly recommend against vitamin E, B6, folic acid (when not deficient), or vitamin D for cognitive improvement 1. Only correct documented deficiencies.

Do not ignore the prognostic significance of p-tau217. This biomarker predicts progression to AD dementia with high accuracy 4, 10. The 2025 Alzheimer's Association guidelines emphasize that p-tau217 and %p-tau217 demonstrated superior diagnostic accuracy over other blood biomarkers in MCI 10.

Expected Outcomes

• Short-term (3 months): Possible modest cognitive improvement from B12 repletion (1-3 point MoCA increase) 2
• Long-term: Progressive cognitive decline likely due to underlying AD pathology indicated by elevated p-tau217 9
• Prognosis: The combination of MCI, MoCA 18/30, and p-tau217 of 0.39 suggests high probability of progression to AD dementia within 3-5 years without disease-modifying treatment 11, 4